Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials

Reuters12-06 11:11

Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials

Shanghai Junshi Biosciences Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced or metastatic esophageal squamous cell carcinoma (ESCC), respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-naïve patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598017-en) on December 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589841661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589841661","market":"nz","top_or_hot":-1,"title":"Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced or metastatic esophageal squamous cell carcinoma (ESCC), respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-naïve patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/688180\">Shanghai Junshi Biosciences</a> Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598017-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-06 11:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced or metastatic esophageal squamous cell carcinoma (ESCC), respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-naïve patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/688180\">Shanghai Junshi Biosciences</a> Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598017-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL6dq5Rj:1","article_id":"2589841661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589841661","pubTimestamp":1764990691,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Junshi Biosciences Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma  and advanced or metastatic esophageal squamous cell carcinoma , respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology  Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-nave patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT stri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK0239":"医药制造","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"君实生物报告特瑞普利单抗在NPC和ESCC试验中获得创纪录的生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"NDAQ":0.9},"content_text":"Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials\n    \n\nShanghai Junshi Biosciences Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) and advanced or metastatic esophageal squamous cell carcinoma (ESCC), respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-naïve patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598017-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589841661","isCrawlerRequest":true}